Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;76(7):e70000.
doi: 10.1111/jpi.70000.

Melatonin Inhibits ET-1 Production to Break Crosstalk Between Prostate Cancer and Bone Cells: Implication for Osteoblastic Bone Metastasis Treatment

Liang-Wei Lin  1 , Tien-Huang Lin  2   3 , Sanskruti Swain  1 , Jen-Kai Fang  4 , Jeng-Hung Guo  1   5 , Shun-Fa Yang  6   7 , Chih-Hsin Tang  1   8   9   10   11
Affiliations

Melatonin Inhibits ET-1 Production to Break Crosstalk Between Prostate Cancer and Bone Cells: Implication for Osteoblastic Bone Metastasis Treatment

Liang-Wei Lin et al. J Pineal Res. 2024 Oct.

Abstract

Bone metastasis is the primary cause of death among patients with advanced prostate cancer (PCa). PCa tends to spread to bones and acquire the bone-like phenotype, causing osteoblastic bone metastasis. Unfortunately, there is no effective treatment for this condition. However, melatonin, which regulates our circadian rhythm, has been found to have anti-tumor properties. It has yet to be established whether it is effective in treating osteoblastic PCa metastasis. Our findings show that melatonin inhibits the production of endothelin-1 (ET-1) in osteoblastic PCa cells, suppressing osteoblast differentiation. Clinical results indicate that bone metastatic PCa patients have higher levels of ET-1 compared to nonmetastatic PCa patients. Furthermore, melatonin-induced miR-let-7f-5p inhibits ET-1-promoted osteoblast differentiation in osteoblastic PCa. Melatonin also suppresses the property of osteomimicry in osteoblastic PCa cells. Importantly, in the intratibia injection PCa metastasis model, melatonin decreased osteoblastic PCa tumor growth, inhibiting ET-1 production and osteoblast differentiation in vivo. Taken together, melatonin inhibits osteoblastic PCa-regulated osteoblastogenesis by reducing ET-1 production through upregulation of miR-let-7f-5p, while suppressing the property of osteomimicry in osteoblastic PCa. Melatonin therapy could be a promising approach to treating bone metastasis in osteoblastic PCa.

Keywords: ET‐1; melatonin; miR‐let‐7f‐5p; osteoblastic prostate cancer; osteoblastogenesis.

PubMed Disclaimer

References

    1. O. Sartor and J. S. de Bono, “Metastatic Prostate Cancer,” New England Journal of Medicine 378, no. 7 (2018): 645–657.
    1. M. Quiroz‐Munoz, S. Izadmehr, D. Arumugam, B. Wong, A. Kirschenbaum, and A. C. Levine, “Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase,” Journal of the Endocrine Society 3, no. 3 (2019): 655–664.
    1. S. C. Lin, L. Y. Yu‐Lee, and S. H. Lin, “Osteoblastic Factors in Prostate Cancer Bone Metastasis,” Current Osteoporosis Reports 16, no. 6 (2018): 642–647.
    1. T. Ibrahim, E. Flamini, L. Mercatali, E. Sacanna, P. Serra, and D. Amadori, “Pathogenesis of Osteoblastic Bone Metastases From Prostate Cancer,” Cancer 116, no. 6 (2010): 1406–1418.
    1. H. C. Tai, S. W. Wang, S. Swain, et al., “Melatonin Suppresses the Metastatic Potential of Osteoblastic Prostate Cancers by Inhibiting Integrin Alpha(2) Beta(1) Expression,” Journal of Pineal Research 72, no. 3 (2022): e12793.

LinkOut - more resources